08/17/21: Additional dose for certain people who are moderately or severely immunocompromised:

Certain people who are moderately or severely immunocompromised due to a medical condition or receipt of immunosuppressive medications or treatments, should consult with their healthcare provider to discuss the benefits of an additional dose of an mRNA (Pfizer or Moderna) vaccine, and receive the additional vaccine dose if indicated. The additional dose of mRNA COVID-19 vaccine is administered at least 4 weeks after the last dose of the primary COVID-19 vaccine series).

For the purposes of this FDA additional dose authorization, persons with the following conditions would
be eligible to receive an additional mRNA COVID-19 vaccine dose:

• Active treatment for solid tumor and hematologic malignancies
• Receipt of solid-organ transplant and taking immunosuppressive therapy
• Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or
  taking immunosuppression therapy)
• Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich
  syndrome)
• Advanced or untreated HIV infection
• Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day),
  alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer
  chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF)
  blockers, and other biologic agents that are immunosuppressive or immunomodulatory.

A patient’s clinical team is best positioned to determine the degree of immune compromise and appropriate timing of the additional (third) dose.

If you are eligible and would like to receive an additional (third) dose, you may schedule an appointment below at a clinic labeled "3rd Dose for Immunocompromised." We request that you bring a letter from your healthcare provider (MD) that: includes your name & date of birth, confirms your eligibility (should not specify condition and/or treatment) and provides a timeframe for when the third dose should be given.